Botanix Pharmaceuticals 관리

관리 기준 확인 1/4

Botanix Pharmaceuticals CEO는 Howie McKibbon, Aug2023 에 임명되었습니다 의 임기는 1.25 년입니다. 총 연간 보상은 A$ 3.92M, 15.3% 로 구성됩니다. 15.3% 급여 및 84.7% 보너스(회사 주식 및 옵션 포함). 는 A$ 1.28M 가치에 해당하는 회사 주식의 0.22% 직접 소유합니다. 1.28M. 경영진과 이사회의 평균 재임 기간은 각각 1 년과 5.3 년입니다.

주요 정보

Howie McKibbon

최고 경영자

AU$3.9m

총 보상

CEO 급여 비율	15.3%
CEO 임기	1.3yrs
CEO 소유권	0.2%
경영진 평균 재임 기간	less than a year
이사회 평균 재임 기간	5.3yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Howie McKibbon 의 보수는 Botanix Pharmaceuticals 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	AU$4m	AU$602k	-AU$14m
Mar 31 2024	n/a	n/a	-AU$12m
Dec 31 2023	n/a	n/a	-AU$10m
Sep 30 2023	n/a	n/a	-AU$10m
Jun 30 2023	AU$1m	AU$542k	-AU$9m
Mar 31 2023	n/a	n/a	-AU$10m
Dec 31 2022	n/a	n/a	-AU$11m
Sep 30 2022	n/a	n/a	-AU$12m
Jun 30 2022	AU$585k	AU$126k	-AU$13m

보상 대 시장: Howie 의 총 보상 ($USD 2.55M )은 Australian 시장( $USD 910.64K ).

보상과 수익: 회사가 수익성이 없는 동안 Howie 의 보상이 증가했습니다.

CEO

Howie McKibbon

1.3yrs

테뉴어

AU$3,923,813

보상

Dr. Howie McKibbon serves as Chief Executive Officer since August 24, 2023 and was its Chief Operating Officer since October 2022 until August 24, 2023. He served as Chief Commercial Officer at Botanix Pha...

리더십 팀

이름	위치	테뉴어	보상	소유권
Vincent Ippolito	MD & Executive Chairman	5.3yrs	AU$612.70k	0.59% A$ 3.5m
Howie McKibbon	Chief Executive Officer	1.3yrs	AU$3.92m	0.22% A$ 1.3m
Graeme Morissey	Chief Financial Officer	less than a year	AU$186.22k	데이터 없음
Matthew Callahan	Executive Director	4.8yrs	AU$357.12k	4.1% A$ 23.9m
Jack Hoblitzell	Senior Vice President of Pharmaceutical Development	3.8yrs	데이터 없음	데이터 없음
Patricia Walker	Chief Medical Adviser	2.8yrs	데이터 없음	데이터 없음
Boris Meyerson	Chief Business Officer	less than a year	데이터 없음	데이터 없음
David Morgan	Head of Corporate Affairs	less than a year	데이터 없음	데이터 없음
Kevin Wojciechowski	Head of HCP Marketing & Sales Training	less than a year	데이터 없음	데이터 없음
Susan Park	Company Secretary	1.6yrs	데이터 없음	데이터 없음
Darin Van Arsdale	Director of Sales Operations	less than a year	데이터 없음	데이터 없음

1.0yrs

평균 재임 기간

58yo

평균 연령

경험이 풍부한 관리: BOT 의 관리팀은 경험 (평균 재직 기간 1 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Vincent Ippolito	MD & Executive Chairman	5.3yrs	AU$612.70k	0.59% A$ 3.5m
Matthew Callahan	Executive Director	4.8yrs	AU$357.12k	4.1% A$ 23.9m
Stewart Washer	Independent Non-Executive Director	5.8yrs	AU$61.57k	0.12% A$ 694.4k
Henry Bosch	Non Executive Director	8.3yrs	AU$227.16k	1.04% A$ 6.0m
Daniel Sharp	Non-Executive Director	2.7yrs	AU$88.49k	0.12% A$ 682.0k

5.3yrs

평균 재임 기간

54yo

평균 연령

경험이 풍부한 이사회: BOT 의 이사회는 경험(평균 재직 기간 5.3 년)으로 간주됩니다.

Botanix Pharmaceuticals 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

Botanix Pharmaceuticals Limited Announces Management Appointments

Botanix Pharmaceuticals Limited, Annual General Meeting, Nov 04, 2024

Botanix Pharmaceuticals Limited, Annual General Meeting, Mar 01, 2024

Botanix Pharmaceuticals Limited, Annual General Meeting, Nov 08, 2023

Botanix Pharmaceuticals Limited Appoints Howie Mckibbon as Chief Executive Officer

Botanix Pharmaceuticals Limited, Annual General Meeting, Sep 18, 2023

Recent updates

Botanix Pharmaceuticals Limited Announces Management Appointments

Botanix Pharmaceuticals Limited, Annual General Meeting, Nov 04, 2024

Full year 2024 earnings released: AU$0.009 loss per share (vs AU$0.008 loss in FY 2023)

Botanix Pharmaceuticals Limited has completed a Follow-on Equity Offering in the amount of AUD 70 million.

New major risk - Financial position

New minor risk - Financial position

Botanix Pharmaceuticals Limited, Annual General Meeting, Mar 01, 2024

Botanix Pharmaceuticals Limited has filed a Follow-on Equity Offering in the amount of AUD 13.5 million.

Botanix Pharmaceuticals Limited has filed a Follow-on Equity Offering in the amount of AUD 13.5 million.

Full year 2023 earnings released: AU$0.008 loss per share (vs AU$0.014 loss in FY 2022)

Botanix Pharmaceuticals Limited, Annual General Meeting, Nov 08, 2023

New minor risk - Financial data availability

Botanix Pharmaceuticals Limited Appoints Howie Mckibbon as Chief Executive Officer

Botanix Pharmaceuticals Limited, Annual General Meeting, Sep 18, 2023

Botanix Pharmaceuticals Limited Announces Confirmation Sofpironium Bromide Nda Formally Under Review

Less than half of directors are independent

Botanix Pharmaceuticals Limited Promotes Howie Mckibbon to Chief Operating Officer

Botanix Pharmaceuticals Limited Announces Positive Data from its BTX 1702 Phase 1B/2 Papulopustular Rosacea Clinical Study

Botanix Pharmaceuticals Limited Submits FDA New Drug Application for Sofpironium Bromide

Botanix Pharmaceuticals Limited, Annual General Meeting, Nov 03, 2022

Full year 2022 earnings released: AU$0.013 loss per share (vs AU$0.003 loss in FY 2021)

Less than half of directors are independent

Botanix Pharmaceuticals Limited Appoints Howie Mckibbon as Chief Commercial Officer and Patricia Walker as Chief Medical Adviser

First half 2022 earnings: EPS in line with analyst expectations despite revenue beat

Botanix Pharmaceuticals Limited Announces Launch of Canine Atopic Dermatitis Program

Full year 2021 earnings released: AU$0.003 loss per share (vs AU$0.018 loss in FY 2020)

Botanix Pharmaceuticals Limited Announces Results from BTX 1204A Pilot Study

First half 2021 earnings released: EPS AU$0.001 (vs AU$0.008 loss in 1H 2020)

Botanix Pharmaceuticals Limited Expands Management Team

Botanix Pharmaceuticals Limited Announces Positive Top-Line Data from BTX 1801 Phase 2A Nasal Decolonisation Proof of Concept Study

Botanix Pharmaceuticals Limited Publishes Antimicrobial Data in Peer-Reviewed Research Journal

Botanix Pharmaceuticals Limited Provides Update on BTX 1801 Phase 2A Clinical Study

Botanix Pharmaceuticals Limited(ASX:BOT) dropped from S&P/ASX Emerging Companies Index

Full year earnings released - AU$0.018 loss per share

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령